NASDAQ:CYTR

LadRx - CYTR Stock Forecast, Price & News

$0.09

+0.09 (+∞)

(As of 10/5/2022)

Add

Compare

Today's Range: $0.09
▼
$0.10
50-Day Range: $0.08
▼
$0.13
52-Week Range: $0.05
▼
$0.86

Volume: 4,000 shs
Average Volume: 99,706 shs
Market Capitalization: $4.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About LadRx (NASDAQ:CYTR) Stock

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

March 22, 2023 | americanbankingnews.com

LadRx (NASDAQ:CYTR) Now Covered by Analysts at StockNews.com

October 5, 2022 | finance.yahoo.com

LadRx Corporation Announces OTCQB Ticker Change to LADX

March 27, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

September 23, 2022 | finance.yahoo.com

CytRx Corporation Relaunches as LadRx Corporation

September 8, 2022 | seekingalpha.com

European patent office awards CytRx patent for LADR platform

September 7, 2022 | finance.yahoo.com

European Patent Office Awards CytRx Key Patent

August 3, 2022 | marketwatch.com

Temperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028

August 2, 2022 | thestreet.com

Whiplash: S&P Veers to All-Time High Before Crashing

March 27, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

May 19, 2022 | finance.yahoo.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

May 18, 2022 | marketwatch.com

Kinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of value

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: Manufacturing
Current Symbol: NASDAQ:CYTR
CUSIP: N/A
CIK: N/A
Web: www.cytrx.com
Phone: (310) 826-5648
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 45,037,000
Free Float: N/A
Market Cap: $4.14 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Stephen Snowdy
Chief Executive Officer

John Y. Caloz
Chief Financial Officer, Treasurer & Senior VP

Felix Kratz
Vice President-Drug Discovery

Cristina Newman
Secretary

Key Competitors

View All Competitors

CYTR Stock - Frequently Asked Questions

How have CYTR shares performed in 2023?: LadRx's stock was trading at $0.0920 at the beginning of 2023. Since then, CYTR stock has increased by 0.0% and is now trading at $0.0920.
View the best growth stocks for 2023 here.
What is LadRx's stock symbol?: LadRx trades on the NASDAQ under the ticker symbol "CYTR."

How do I buy shares of LadRx?: Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is LadRx's stock price today?: One share of CYTR stock can currently be purchased for approximately $0.09.
How much money does LadRx make?: LadRx (NASDAQ:CYTR) has a market capitalization of $4.14 million.
How can I contact LadRx?: LadRx's mailing address is 11726 San Vicente Blvd Ste 650, Los Angeles, California 90049-5079. The official website for the company is www.cytrx.com. The company can be reached via phone at (310) 826-5648.

This page (NASDAQ:CYTR) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial